Orum Therapeutics Gains FDA Clearance for ORM-1153
Boston, Massachusetts, USA, and Daejeon, South Korea, August 22, 2026 Orum Therapeutics, a biotechnology company developing degrader-antibody conjugates (DACs)...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Boston, Massachusetts, USA, and Daejeon, South Korea, August 22, 2026 Orum Therapeutics, a biotechnology company developing degrader-antibody conjugates (DACs)...
New York, New York, USA, August 20, 2026 Protagenic Therapeutics, a clinical-stage biopharmaceutical company developing peptide-based treatments for stress-related...
Waltham, Massachusetts, USA, and San Diego, California, USA, August 21, 2026 Werewolf Therapeutics and Ambros Therapeutics have announced a...
